The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
- P. Jain,
- H. Kantarjian,
- F. Ravandi,
- D. Thomas,
- S. O'Brien,
- T. Kadia
- University of Texas Health Science Center at Houston
Scholary Output:
Contribution to journal
Letter
Peer-reviewSustainable Development Goals
SDG 3 Good Health and Well
Publication Information
Output type
Scholary Output:
Contribution to journal
Letter
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 973-975 (3 pages)Journal (Volume, Issue Number)
Leukemia (Volume 28, Issue 4)Publication milestones
- Published - 04/2014
Publication status
Published - 04/2014
ISSN
0887-6924Publication IDs
- Scopus: 84898402916
- PubMed: 24157581
- ORCID: /0000-0002-8636-1071/work/68888170
Publication metrics
Metrics
Fractional count
1
Fractional count
0.06
Fractional count
16
Fractional count
0.94
Fractional count
1
Fractional count
1
SciVal
citations
32
SciVal
FWCI
5.03
SciVal
Author count
17
SciVal
Paper percentile
89
PlumX, opens in new tab
Citation count
52
Captures
61
Funding Details
This study was supported partly by GlaxoSmithKline Pharmaceuticals (to SF).
FundersFunding number
NCI
P30CA016672
GSK
-